24 hr lamotrigine 25 mg extended release oral tablet
1 INDICATIONS AND USAGE Lamotrigine extended-release tablets are indicated for: adjunctive therapy for primary generalized tonic-clonic seizures and partial-onset seizures with or without secondary generalization in patients aged 13 years and older. ( 1.1 ) conversion to monotherapy in patients aged 13 years and older with partial-onset seizures who are receiving treatment with a single antiepileptic drug. ( 1.2 ) Limitation of use: Safety and effectiveness in patients younger than 13 years have not been established. ( 1.3 ) 1.1 Adjunctive Therapy Lamotrigine extended-release tablets are indicated as adjunctive therapy for primary generalized tonic-clonic (PGTC) seizures and partial-onset seizures with or without secondary generalization in patients aged 13 years and older. 1.2 Monotherapy Lamotrigine extended-release tablets are indicated for conversion to monotherapy in patients aged 13 years and older with partial-onset seizures who are receiving treatment with a single antiepileptic drug (AED). Safety and effectiveness of lamotrigine extended-release tablets have not been established (1) as initial monotherapy or (2) for simultaneous conversion to monotherapy from 2 or more concomitant AEDs. 1.3 Limitation of Use Safety and effectiveness of lamotrigine extended-release tablets for use in patients younger than 13 years have not been established.
trupharma, llc
ROUND BLUE H011
Related Pills
24 hr lamotrigine 25 mg extended release oral tablet
trupharma, llc
24 hr lamotrigine 25 mg extended release oral tablet
trupharma, llc
24 hr lamotrigine 25 mg extended release oral tablet
trupharma, llc
DISCLAIMER:
"This tool does not provide medical advice, and is for informational and educational purposes only, and is not a substitute for professional medical advice, treatment or diagnosis. Call your doctor to receive medical advice. If you think you may have a medical emergency, please dial 911."
"Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service."
"This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product."
PillSync may earn a commission via links on our site
16 HOW SUPPLIED/STORAGE AND HANDLING Lamotrigine Extended-Release Tablets, USP 25 mg, white to off-white, round, film-coated tablets engraved with “H008” on one side and plain on the other side supplied in unit-of-use bottles of 30 tablets (NDC 52817-240-30). 50 mg, peach, round, film-coated tablets engraved with “H009” on one side and plain on the other side supplied in unit-of-use bottles of 30 tablets (NDC 52817-241-30). 100 mg, yellow, round, film-coated tablets engraved with “H012” on one side and plain on the other side supplied in unit-of-use bottles of 30 tablets (NDC 52817-242-30). 200 mg, blue, round, film-coated tablets engraved with “H011” on one side and plain on the other side supplied in unit-of-use bottles of 30 tablets (NDC 52817-243-30). Storage Store at 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature].
More pills like ROUND H011